Key result
Assessment of myocardial viability might not be the sole deciding factor in selecting the best therapy for patients with ischemic left ventricular dysfunction, as recent trials show a lack of interaction between viability and revascularization benefit.
Population
Patients with coronary artery disease and ischemic left ventricular (LV) dysfunction
Design
Review
Authors
Loading...
Viability testing may not solely guide therapy in ischemic LV dysfunction; leaves open optimal selection criteria for revascularization.
This review discusses the modalities for assessing myocardial viability and the clinical impact of revascularization in patients with ischemic left ventricular dysfunction.
Singh et al. (2015) conducted a review in Ischemic left ventricular dysfunction. Revascularization vs. Medical therapy was evaluated. Assessment of myocardial viability might not be the sole deciding factor in selecting the best therapy for patients with ischemic left ventricular dysfunction, as recent trials show a lack of interaction between viability and revascularization benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: